Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.48 USD
Change Today -0.05 / -1.10%
Volume 399.3K
SQNM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:37 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

sequenom inc (SQNM) Key Developments

Sequenom Inc. Proposes Amendment to its Restated Certificate of Incorporation

Sequenom Inc. announced that the annual general meeting to be held on June 17, 2015, it has proposed an amendment to the company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 185,000,000 to 275,000,000 shares.

Sequenom Inc. to Report Q1, 2015 Results on May 06, 2015

Sequenom Inc. announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on May 06, 2015

Sequenom Inc., Q1 2015 Earnings Call, May 06, 2015

Sequenom Inc., Q1 2015 Earnings Call, May 06, 2015

Sequenom Inc. Announces Board Changes

Sequenom Inc. announced that its board of directors elected Kenneth Buechler as chairman of the board, effective April 1, 2015. Dr. Buechler succeeds Harry Hixson, who will retire from the position effective March 31, 2015, after 11 years of service. Incoming chairman, Dr. Buechler, has served on the board of directors since December 2009. Prior to joining Sequenom's board, he served as president and chief scientific officer of Biosite Incorporated.

Sequenom Inc. Announces Board Changes, Effective April 1, 2015

Sequenom Inc. Board of Directors elected Dirk van den Boom, Ph.D., current Executive Vice President, Chief Scientific and Strategy Officer, as a director, effective April 1, 2015. In addition, the Board of Directors appointed Dr. van den Boom to the Science Committee of its Board of Directors, also effective April 1, 2015. Dr. van den Boom will fill the vacancy created by the resignation of Harry F. Hixson, Jr., Ph.D. as a director, which resignation is effective March 31, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SQNM:US $4.48 USD -0.05

SQNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $22.64 USD -0.28
Cerus Corp $4.62 USD +0.13
Luminex Corp $16.36 USD -0.15
Pacific Biosciences of California Inc $6.15 USD +0.32
STAAR Surgical Co $8.88 USD -0.10
View Industry Companies
 

Industry Analysis

SQNM

Industry Average

Valuation SQNM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.6x
Price/Book NM Not Meaningful
Price/Cash Flow 542.6x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEQUENOM INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.